At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CAI Caris Life Sciences, Inc.
Pre-Mkt 10-19 07:24:27 EDT
30.56
-1.20
-3.78%
盘前30.71
+0.15+0.49%
05:39 EDT
High32.40Low30.16Vol2.73M
Open31.76D1 Closing31.76Amplitude7.07%
Mkt Cap8.62BTradable Cap3.54BTotal Shares282.15M
T/O84.05MT/O Rate2.35%Tradable Shares116.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

US Research Roundup-Analog Devices, IBM, Qualcomm
Reuters  ·  15:31
US Research Roundup-Analog Devices, IBM, Qualcomm
Caris Life Sciences, Inc. : Canaccord Genuity Raises Target Price to $30 from $22
THOMSON REUTERS  ·  12:30
Caris Life Sciences, Inc. : Canaccord Genuity Raises Target Price to $30 from $22
Movement Alert｜Caris Life Sciences, Inc. Falls 5.05% in Regular Trading, Profit-Taking Emerges After BofA Target Price Increase
Market Focus  ·  10-17 03:10
Movement Alert｜Caris Life Sciences, Inc. Falls 5.05% in Regular Trading, Profit-Taking Emerges After BofA Target Price Increase
Movement Alert｜Caris Life Sciences, Inc. Rises 5.11% in Regular Trading, BofA Lifts Price Target to 35 USD
Market Focus  ·  10-16
Movement Alert｜Caris Life Sciences, Inc. Rises 5.11% in Regular Trading, BofA Lifts Price Target to 35 USD
CAI Corp Updates Investors on HK$0.15 Net Asset Value Per Share
TIPRANKS  ·  10-15
CAI Corp Updates Investors on HK$0.15 Net Asset Value Per Share
Caris Life Sciences Price Target Raised to $35.00/Share from $25.00 by JP Morgan
Dow Jones  ·  10-15
Caris Life Sciences Price Target Raised to $35.00/Share from $25.00 by JP Morgan
Movement Alert｜Caris Life Sciences, Inc. Intraday Rise 5.99% in Regular Trading, BofA Securities Raised Price Target to $35
Market Focus  ·  10-14
Movement Alert｜Caris Life Sciences, Inc. Intraday Rise 5.99% in Regular Trading, BofA Securities Raised Price Target to $35
Caris Life Sciences to Present CapeAI Study Predicting Capecitabine Response in ER+ Breast Cancer at ESMO 2026
Reuters  ·  10-14
Caris Life Sciences to Present CapeAI Study Predicting Capecitabine Response in ER+ Breast Cancer at ESMO 2026
Caris Life Sciences is Maintained at Buy by TD Cowen
Dow Jones  ·  10-14
Caris Life Sciences is Maintained at Buy by TD Cowen
CAI Corp Plans New Memorandum and Articles to Meet Hong Kong Rule Changes
TIPRANKS  ·  10-12
CAI Corp Plans New Memorandum and Articles to Meet Hong Kong Rule Changes
Movement Alert｜Caris Life Sciences Rises 5.07% in Regular Trading, BofA Raises Price Target to $35 Boosting Precision Medicine Sentiment
Market Focus  ·  10-09
Movement Alert｜Caris Life Sciences Rises 5.07% in Regular Trading, BofA Raises Price Target to $35 Boosting Precision Medicine Sentiment
BofA Securities Adjusts Caris Life Sciences Price Target to $35 From $23
MT Newswires Live  ·  10-09
BofA Securities Adjusts Caris Life Sciences Price Target to $35 From $23
Movement Alert｜Caris Life Sciences, Inc. Rises 5.59% in Regular Trading on Strong Precision Oncology Momentum
Market Focus  ·  10-06
Movement Alert｜Caris Life Sciences, Inc. Rises 5.59% in Regular Trading on Strong Precision Oncology Momentum
Movement Alert｜Caris Life Sciences, Inc. Rises 5.65% in Regular Trading, Trading at $29.89
Market Focus  ·  10-06
Movement Alert｜Caris Life Sciences, Inc. Rises 5.65% in Regular Trading, Trading at $29.89
Movement Alert｜Caris Life Sciences, Inc. Falls 5.06% in Regular Trading, Trading at $29.09
Market Focus  ·  10-02
Movement Alert｜Caris Life Sciences, Inc. Falls 5.06% in Regular Trading, Trading at $29.09
Caris Life Sciences SVP, General Counsel John Russel Denton Disposes of 7,500 Shares Worth $238,626.00
Reuters  ·  09-24
Caris Life Sciences SVP, General Counsel John Russel Denton Disposes of 7,500 Shares Worth $238,626.00
Movement Alert｜Caris Life Sciences, Inc. Rises 5.38% in Regular Trading, Trading at $32.22
Market Focus  ·  09-22
Movement Alert｜Caris Life Sciences, Inc. Rises 5.38% in Regular Trading, Trading at $32.22
Caris Life Sciences Vice Chairman Brian J. Brille Disposes of 400,000 Common Shares for $12.13 Million
Reuters  ·  09-18
Caris Life Sciences Vice Chairman Brian J. Brille Disposes of 400,000 Common Shares for $12.13 Million
Movement Alert｜Caris Life Sciences, Inc. Rises 5.35% in Regular Trading, Earnings Beat and Institutional Coverage Continue to Boost Sentiment
Market Focus  ·  09-17
Movement Alert｜Caris Life Sciences, Inc. Rises 5.35% in Regular Trading, Earnings Beat and Institutional Coverage Continue to Boost Sentiment
CAI Corp Switches Auditor as Business Expansion Drives Greater Audit Demands
TIPRANKS  ·  09-17
CAI Corp Switches Auditor as Business Expansion Drives Greater Audit Demands

Introduction

Company Name.
Caris Life Sciences, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Caris Life Sciences, Inc. is a leading patient-centered next-generation artificial intelligence technology biology company and precision medicine pioneer. It develops and commercializes innovative solutions to transform health care through the large-scale use of comprehensive molecular information and AI/ML algorithms. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology and serving the clinical, academic and biopharmaceutical markets.
Issue price:
--